1. ACL - FDA approved generic selling now, phase 2 trials for small cell lung cancer underway and has had great results already 80 - 100% tumour reduction, phase 3 trials for colorectal cancer starting this year also. Funding is to be announced soon and might release sp once known, well oversold considering their position.
2. TIS - has been talked about on the thread already. Good near term milestones coming up.
3. GTG - Maiden profit earned last FY. BREVAGen product now in market with a $620m pa addressable US market, cashed up and listed on NASDAQ also.
Top 3 for me, world markets holding up of course:)
the biotech sector, page-21
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)